The global AMD drugs market is set to grow from USD 10.46 billion in 2024 to USD 17.37 billion by 2029, reflecting a robust ...

Researchers found that metformin, a diabetes medication, may reduce the risk of age-related macular degeneration (AMD). Their ...

The quest to find a cure for the UK’s biggest cause of sight loss will be brought sharply into focus at a support group for ...

Ocugen (OCGN) reported that the FDA has lifted the clinical hold on the investigational new drug application for the Phase 1 clinical ...

Ocugen said the Food and Drug Administration lifted a clinical hold on its OCU200 investigational treatment for diabetic macular edema, paving the way for Phase 1 trials.

Age-related macular degeneration (AMD ... some researchers have turned their attention to metformin—a drug better known for treating type 2 diabetes—because of promising data on its overall ...

Ocugen (NASDAQ:OCGN) said the FDA has removed a clinical hold on its Investigational New Drug application for a Phase 1 study ...

Clearside Biomedical today announced that the ODYSSEY study of its drug-device combination achieved its primary and secondary ...

The European Medicines Agency (EMA) has announced its approval of two new biosimilar medications, Afqlir and Opuviz, to treat age-related macular degeneration ... The drug is initiated with ...